Evidence map›Paper›PMID 33461509›Full record

ArticleBMC surgery2021

Impact of a pandemic on surgical neuro-oncology-maintaining functionality in the early phase of crisis.

N U Farrukh Hameed, Yixin Ma, Zili Zhen, Shuai Wu, Rui Feng, Weiping Li, Guodong Huang, Jinsong Wu, Zhongping Chen

Abstract read
In one paragraph

Article in BMC surgery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. How has the COVID-19 pandemic impacted clinical care and research in Neuro-Oncology?Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia · 2022
    Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

N U Farrukh HameedDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, 201206, China.
Yixin MaDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, 201206, China.
Zili ZhenDepartment of General Surgery, Jinshan Hospital, Fudan University, Shanghai, 201206, China.
Shuai WuDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, 201206, China.
Rui FengDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, 201206, China.
Weiping LiDepartment of Neurosurgery, The First Affiliated Hospital of Shenzhen University, Shenzhen, 518035, China.
Guodong HuangDepartment of Neurosurgery, The First Affiliated Hospital of Shenzhen University, Shenzhen, 518035, China.
Jinsong WuDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, 201206, China.
Zhongping ChenDepartment of Neurosurgery, The First Affiliated Hospital of Shenzhen University, Shenzhen, 518035, China. chenzhp@sysucc.org.cn.ORCID http://orcid.org/0000-0002-6226-5771

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Coronavirus disease 2019 (COVID-19) pandemic has extraordinarily impacted global healthcare. Neuro-oncological surgery units have peculiar features that make them highly relevant in the strategic reaction to the pandemic. In this Chinese Society of Neuro-Oncology (CSNO) initiated survey, we appraise the changes implemented in neuro-oncological surgery hospitals across different Asian countries and provide expert recommendations for responses at different stages of the pandemic.

methodsWe performed a 42-question survey of the early experience of neuro-oncological surgery practice in hospitals across different Asian countries on April 1, 2020, with responses closed on April 18, 2020.

results144 hospitals completed the questionnaire. Most were in WHO post-peak phase of the pandemic and reported a median reduction in neuro-oncological surgery volume of 25-50%. Most (67.4%) resumed elective surgery in only COVID-19 negative patients;11.1% performed only emergency cases irrespective of COVID-19 status;2.1% suspended all surgical activity. Ninety-one (63.2%) relocated personnel from neurosurgery to other departments. Fifty-two (36.1%) hospitals suspended post-operative adjuvant therapy and 94 (65.2%) instituted different measures to administer post-operative adjuvant therapy. Majority (59.0%) of the hospitals suspended research activity. Most (70%) respondents anticipate that current neurosurgery restrictions will continue to remain for > 1 month.

conclusionsMajority of the respondents to our survey reported reduced neuro-oncological surgery activity, policy modification, personnel reallocation, and curtailment of educational/research activities in response to the COVID-19 pandemic. The persistent widespread interruption of surgical neuro-oncology in even post-peak phases of the pandemic raises serious concerns about the long-term impact of the pandemic on neuro-oncological patients and highlights the essence of timely measures for pandemic preparedness, patient triage, and workforce protection.

Indexed as

COVID-19NeurosurgeryNeurosurgical ProceduresPandemicsElective Surgical ProceduresHumansSARS-CoV-2COVID-19Neuro-oncological surgeryNeuro-oncologyNeurosurgeryPandemic

Identifiers

PMID33461509
PMCPMC7812331

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.